These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26811660)

  • 1. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
    Shao YG; Ning K; Li F
    World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P21 activated kinase signaling in cancer.
    Rane CK; Minden A
    Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of p21-activated kinases (PAKs).
    Rudolph J; Crawford JJ; Hoeflich KP; Wang W
    J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p21-activated kinases in pancreatic cancer.
    Yeo D; He H; Baldwin GS; Nikfarjam M
    Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of p-21-activated kinases in cancer progression.
    King H; Nicholas NS; Wells CM
    Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
    Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
    Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho family GTPase signaling through type II p21-activated kinases.
    Chetty AK; Ha BH; Boggon TJ
    Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
    Wu A; Jiang X
    Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21-activated kinase inhibitors.
    Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
    Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.
    Yi C; Maksimoska J; Marmorstein R; Kissil JL
    Biochem Pharmacol; 2010 Sep; 80(5):683-9. PubMed ID: 20302846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21-activated kinase 1: PAK'ed with potential.
    Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
    Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting group II PAKs in cancer and metastasis.
    Eswaran J; Soundararajan M; Knapp S
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):209-17. PubMed ID: 19160016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK as a therapeutic target in gastric cancer.
    Li X; Liu F; Li F
    Expert Opin Ther Targets; 2010 Apr; 14(4):419-33. PubMed ID: 20146633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of p21-activated kinases in cardiovascular development and function.
    Kelly ML; Astsaturov A; Chernoff J
    Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
    Gul M; Fakhar M; Najumuddin ; Rashid S
    PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
    Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
    Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
    Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracing PAKs from GI inflammation to cancer.
    Dammann K; Khare V; Gasche C
    Gut; 2014 Jul; 63(7):1173-84. PubMed ID: 24811999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
    McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
    Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.